Nasus Pharma (NSRX) Short term Debt (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Short term Debt came in at $2.6 million in Q2 2025, up 42.23% on a QoQ basis from $1.8 million in Q4 2024.
Nasus Pharma (NSRX) Short term Debt (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Short term Debt data on file, last reported at $2.6 million in Q2 2025.
- Quarterly Short term Debt changed N/A year-over-year to $2.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.6 million (changed N/A YoY) and the FY2024 annual result came in at $1.8 million, changed N/A from the prior year.
- Short term Debt grew to $2.6 million in Q2 2025, from $1.8 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $2.6 million in Q2 2025 to a low of $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.14 Bn | 633.38 Bn | 17.26 Bn |
| 2 | AbbVie | 470.43 Bn | 463.86 Bn | 12.70 Bn |
| 3 | Merck | 375.33 Bn | 368.19 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.82 Bn | 295.13 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.71 Bn | 252.81 Bn | 12.86 Bn |
| 6 | Amgen | 237.15 Bn | 223.17 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.03 Bn | 179.85 Bn | 6.22 Bn |
| 8 | Pfizer | 160.08 Bn | 148.39 Bn | 10.94 Bn |
| 9 | Gsk | 106.10 Bn | 101.93 Bn | 8.24 Bn |
| 10 | Nasus Pharma | 31.24 Mn | 31.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.56 Mn |
| Dec 31, 2024 | 1.80 Mn |